Resamirigene Bilparvovec

N/A

Report date: 2024/05/21 14:56:42

Base Information

Drug NameResamirigene Bilparvovec
Drug Alias NameAT-001 - Astellas Gene Therapies/GenethonAT-001AT-132(Audentes Therapeutics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionGene transferenceMyotubularin expression stimulants
TargetsMyotubularin
Therapy Area/IndicationsMyopathies, Structural, Congenital
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenethonAudentes Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Gene Therapies IncAstellas Pharma Inc
Inactive CompaniesN/A
Active IndicationsMyopathies, Structural, Congenital
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A